ClinicalTrials.gg
Not yet recruitingNCT07740070SEQUOIAUpdated Jul 31, 2026

Cognitive Processing of Natural Sequences in Humans and Artificial Intelligence (AI)

An observational study in Hearing Disorders and Deafness, sponsored by Institut Pasteur. Not yet recruiting. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-31.

Primary conditionDeafnessRegistry: Hearing DisordersReclassifiedWhy we changed it
Registry
Hearing Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Deafness
Why
  1. The study's listed conditions name Deafness, a narrower term within Hearing Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Institut Pasteur · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
700
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The goal of this study is to identify electrical patterns in the cortex that enable the generation of predictions in natural auditory sequences such as speech and music.

Between 500 and 700 participants in total (250 to 350 normally hearing participants (including 60 to 120 participants from West Africa and 60 to 120 participants from Western Europe) and 250 to 350 participants with hearing loss (no restrictions on origin)).

Participants will listen to naturally recorded music and speech via headphones. They will be asked to rate these stimuli on a scale from 0 to 10 in terms of pleasure and comprehension, using a keyboard and mouse or voice input. Additionally, they will be required to sing or produce novel/improvised vocal responses using high-fidelity microphones. This entire procedure will be conducted under electroencephalography (EEG) to record neuronal responses throughout the process.

02

Conditions studied

  • Hearing Disorders and Deafness

Browse trials for

03

In context

Deafness Reclassified

160 studies on the registry are indexed under Deafness; 46 are open to participants now.

This study's planned enrollment of 700 is above the median of 101 across 47 observational studies indexed under Deafness.

Browse Deafness studies →

Lead sponsor

Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.

Compared within Deafness, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hearing Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Hearing participants will be recruited from the general population in the Paris region.

We will also recruit participants with hearing impairment through ENT clinics, in hearing aid dispensing centers.

Finally, we will specifically recruit participants residing in Paris and of West African origin to examine differences related to cultural experience.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For hearing participants:

  • Average pure-tone thresholds ≤ 20 dB HL

For participants with hearing loss:

  • Average pure-tone thresholds > 20 dB HL

For participants of West African origin:

  • Average pure-tone thresholds ≤ 20 dB HL
  • Declare that both parents are of West African origin, either by their own birth or by the birth of both of their parents.

Exclusion criteria

Exclusion Criteria:

  • No known neurological or audiological disorders
  • Participants under legal guardianship (tutelle, curatelle)
  • Participants deprived of legal liberty by judicial or administrative decision
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No

Groups and cohorts

  • Normal hearing participants from West Africa
  • Normal hearing participants from Western Europe
  • Participants with hearing loss
06

What researchers measure

Primary outcomes

  1. Correlation between neural recordings and IA models

    To identify electrical patterns in cortex which generates predictions in natural auditory sequences (such as speak and music).

    Time frame: Day 1

Secondary outcomes

  1. Compare predictions generated across different cultural contexts

    specifically, comparing West African and Western European communities in Paris

    Time frame: Day 1

  2. Compare predictions for identical stimuli across repeated sessions to establish a link between processing and successful memorization/retention.

    Time frame: From enrollement to visit 2 (10 days)

  3. Compare predictions generated between hearing individuals and those with hearing impairments.

    Time frame: Day 2

  4. Correlate predictive measures with responses to autism symptom questionnaires across the various experiments.

    Time frame: Day 1

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07740070
Lead sponsor
Institut Pasteur
Collaborators
IHU reConnect
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Sep 2026 (estimated)
Primary completion
Nov 2030 (estimated)
Completion
Nov 2033 (estimated)
Last update
Jul 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion